Adenovirus-mediated Aurora A shRNA driven by stathmin promoter suppressed tumor growth and enhanced paclitaxel chemotherapy sensitivity in human breast carcinoma cells-Reference-Cited by-同舟云学术

Adenovirus-mediated Aurora A shRNA driven by stathmin promoter suppressed tumor growth and enhanced paclitaxel chemotherapy sensitivity in human breast carcinoma cells

Published:2012-01-27 Issue:4 Volume:19 Page:271-281
ISSN:0929-1903
Container-title:Cancer Gene Therapy
language:en
Short-container-title:Cancer Gene Ther

Author:

Long M,Yin G,Liu L,Lin F,Wang X,Ren J,Wei J,Dong K,Zhang H

Publisher

Springer Science and Business Media LLC

Subject

Cancer Research,Molecular Biology,Molecular Medicine

Link

http://www.nature.com/articles/cgt201189.pdf

Reference35 articles.

1. Beslija S, Bonneterre J, Burstein H, Cocquyt V, Gnant M, Goodwin P et al. Second consensus on medical treatment of metastatic breast cancer. Ann Oncol 2007; 18: 215–225.

2. Biganzoli L, Minisini A, Aapro M, Di Leo A . Chemotherapy for metastatic breast cancer. Curr Opin Obstet Gynecol 2004; 16: 37–41.

3. Glover DM, Leibowitz MH, McLean DA, Parry H . Mutations in aurora prevent centrosome separation leading to the formation of monopolar spindles. Cell 1995; 81: 95–105.

4. Andrews PD, Knatko E, Moore WJ, Swedlow JR . Mitotic mechanics: the auroras come into view. Curr Opin Cell Biol 2003; 15: 672–683.

5. Liu XS, Shi Y, Woods KW, Hessler P, Kroeger P, Wilsbacher J et al. Akt inhibitor A-443654 interferes with mitotic progression by regulating Aurora A kinase expression. Neoplasia 2008; 10: 828–837.

Cited by 20 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Synergistic antitumor immune response mediated by paclitaxel-conjugated nanohybrid oncolytic adenovirus with dendritic cell therapy;Frontiers in Immunology;2024-05-21

2. Cytoskeletal and Cytoskeleton-Associated Proteins: Key Regulators of Cancer Stem Cell Properties;Pharmaceuticals;2022-11-08

3. Noncoding RNAs and their therapeutics in paclitaxel chemotherapy: Mechanisms of initiation, progression, and drug sensitivity;Journal of Cellular Physiology;2022-04-18

4. Tau and stathmin proteins in breast cancer: A potential therapeutic target;Clinical and Experimental Pharmacology and Physiology;2022-02-09

5. Formulation of polymeric nanoparticles loaded sorafenib; evaluation of cytotoxicity, molecular evaluation, and gene expression studies in lung and breast cancer cell lines;Nanotechnology Reviews;2022-01-01